Skip to content

Fatigue in Primary Sjögren's Syndrome

The Level of Fatigue and Its Relationship With Disease Activity, Pain, Insomnia, and Psychometric Parameters in Primary Sjögren's Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04802577
Enrollment
110
Registered
2021-03-17
Start date
2021-01-04
Completion date
2021-07-30
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sjogren's Syndrome, Fatigue, Pain Syndrome, Depression, Anxiety, Fibromyalgia

Brief summary

Fatigue is a common clinical finding in Primary Sjögren's syndrome (PSS). In PSS, there is not enough data about the conditions in which fatigue develops and which clinical conditions the disease is associated with. This study was aimed to determine the level of fatigue in Primary Sjögren syndrome and to investigate the factors affecting the level of fatigue.

Detailed description

While fatigue is seen with a prevalence of 7-8% in the normal population, it is more prevalent in Primary Sjögren's syndrome (PSS). In the studies conducted so far, the frequency of fatigue was seen at a frequency of over 30% in Primary Sjögren's syndrome. Although fatigue is so common in PSS, there is not enough data about the conditions in which fatigue develops in PSS. Other common conditions in PSS, apart from fatigue, are psychometric disorders such as common pain, depression and anxiety, and sleep disorders. In the studies conducted so far, each situation mentioned is common in PSS and seems to be related to each other. In the literature, there is no data on how many psychometric parameters, pain level, and insomnia affect fatigue and which are independent risk factors in PSS.

Interventions

DIAGNOSTIC_TESTFACT-F questionnaire

The questionnaire, based on patient report outcome data in which the presence of fatique is investigated in participants.

The questionnaire, based on patient report outcome data in which the presence of depression is investigated in participants.

DIAGNOSTIC_TESTBeck Anxiety Inventory

The questionnaire, based on patient report outcome data in which the presence of anxiety is investigated in participants.

The questionnaire, based on patient report outcome data in which the presence of insomnia is investigated in participants.

OTHERESSPRI

The questionnaire, based on patient report outcome data in which the severity of Sjögren's syndrome is investigated in participants.

OTHERESSDAI

Activity scale in which the activity of Sjögren's syndrome is evaluated based on the laboratory and imaging tests of the patients and the examination findings of the evaluator.

OTHERPain Detect Questionnaire

The questionnaire, based on patient report outcome data in which the severity and extent of pain in the body are investigated in participants.

Sponsors

Bursa Yuksek Ihtisas Training and Research Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years

Inclusion criteria

* Patients diagnosed with PSS according to the 2016 ACR / EULAR criteria * Healthy hospital staff

Exclusion criteria

* Pregnant women * Cancer patients * Those with other connective tissue diseases other than PSS * Multiple sclerosis patients * Chronic obstructive pulmonary disease * Those with heart failure and adrenal insufficiency * Those with renal failure: GFR \<60 ml/min * Anemia: Hemoglobin \<11 g / dl in women, hemoglobin \<12 g / dl in men * Hypothyroidism: TSH \>5 mu / L * Those with electrolyte disturbance

Design outcomes

Primary

MeasureTime frameDescription
FACIT-Fday 1FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATİQUE

Secondary

MeasureTime frameDescription
BDIday 1Beck Depression Inventory
BAIday 1Beck Anxiety Inventory
ISSday 1Insomnia Severity Scale
PDQday 1Pain Detect Questionnaire

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026